A functional comparison of canine and murine bone marrow derived cultured mast cells.
Disorders involving mast cells are extremely common in dogs, ranging from allergic diseases to neoplastic transformation resulting in malignant mast cell tumors. Relatively little is known regarding the basic biologic properties of normal canine mast cells, largely due to the difficulty in reliably purifying large numbers from canine skin. In vitro generated bone marrow derived cultured mast cells (BMCMCs) are routinely used in both human and murine studies as a ready source of material for in vitro and in vivo studies. We previously developed a technique to generate canine BMCMCs from bone marrow derived CD34+ cells and demonstrated that these cells exhibit the phenotypic properties characteristic of mast cells and release histamine in response to IgE cross-linking. The purpose of the following study was to characterize the functional properties of these canine BMCMCs and contrast these with the functional properties of murine BMCMCs. Our work demonstrates that both IL-4 and IL-10 promote canine BMCMC proliferation, possibly through upregulation of Kit expression, while TGFbeta inhibits proliferation. The canine BMCMCs produce a variety of cytokines and chemokines in response to IgE cross-linking and chemical stimulation including IL-3, IL-4, IL-13, GM-CSF, RANTES, and MIP1alpha. Interestingly, the canine BMCMCs released significantly larger amounts of MCP-1 and tryptase and significantly smaller amounts of IL-6 following chemical stimulation and IgE cross-linking when compared to murine BMCMCs. Lastly, the canine BMCMCs produced larger amounts of active MMP9 than their murine counterparts. In summary, canine BMCMCs exhibit unique functional properties that distinguish them from murine BMCMCs and provide insight into the contribution of these cells to mast cell disorders in the dog.
Lin
Tzu-Yin
TY
Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, 1925 Coffey Road, Columbus, OH 43210, USA.
London
Cheryl A
CA
D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology / Q000276:immunology*; D015550:Cell Degranulation / Q000187:drug effects / Q000276:immunology; D049109:Cell Proliferation / Q000187:drug effects*; D018925:Chemokines / Q000235:genetics / Q000276:immunology*; D004285:Dogs / Q000276:immunology*; D005260:Female; D007073:Immunoglobulin E / Q000276:immunology; D008297:Male; D008407:Mast Cells / Q000166:cytology / Q000201:enzymology / Q000276:immunology*; D020780:Matrix Metalloproteinase 9 / Q000032:analysis / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL / Q000276:immunology*; D019009:Proto-Oncogene Proteins c-kit / Q000276:immunology; D012313:RNA / Q000737:chemistry / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D051193:Toll-Like Receptors / Q000235:genetics / Q000276:immunology; D053802:Tryptases / Q000032:analysis / Q000276:immunology
D018925:Chemokines; D051193:Toll-Like Receptors; D007073:Immunoglobulin E; D012313:RNA; D019009:Proto-Oncogene Proteins c-kit; D053802:Tryptases; D020780:Matrix Metalloproteinase 9